期刊
PHARMACEUTICALS
卷 6, 期 12, 页码 1475-1506出版社
MDPI
DOI: 10.3390/ph6121475
关键词
angiogenesis; autophagy; imidazotetrazine; MGMT; DNA repair; temozolomide; cancer stem cells
资金
- National Institutes of Health under National Center for Advancing Translational Sciences [RO1 NS021716, UL1TR000161]
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据